|
Teva Presents New Data on QNASL(TM) at the 2011 American College of Allergy …
MarketWatch (press release) In addition, the presence of co-morbidities such as asthma and sinusitis further increase AR-related treatment costs. QNASL(TM) is an investigational intranasal corticosteroid in development for the treatment of allergic rhinitis symptoms. … Teva Presents New Data On QNASL™ At The 2011 American College Of Allergy … |
View full post on asthma – Google News